uniQure (NASDAQ:QURE) Director Sells $225,408.15 in Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 5,295 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $42.57, for a total transaction of $225,408.15. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at $1,106,649.72. The trade was a 16.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total value of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Price Performance

Shares of NASDAQ QURE opened at $46.29 on Monday. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -13.30 and a beta of 0.98. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average of $24.74 and a two-hundred day moving average of $22.17.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. As a group, analysts expect that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

QURE has been the subject of several research analyst reports. Royal Bank Of Canada increased their price objective on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a report on Wednesday, June 17th. Finally, Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Twelve equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.92.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in QURE. Militia Capital Management LLC acquired a new stake in uniQure in the 1st quarter valued at about $1,540,000. Flax Pond Capital LLC increased its holdings in uniQure by 3.8% in the first quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock valued at $2,486,000 after purchasing an additional 5,533 shares during the last quarter. Stempoint Capital LP grew its holdings in uniQure by 79.5% during the first quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock valued at $1,276,000 after purchasing an additional 34,581 shares during the period. Irenic Capital Management LP bought a new position in shares of uniQure during the first quarter worth $1,635,000. Finally, Readystate Asset Management LP grew its stake in uniQure by 39.6% in the first quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock valued at $8,252,000 after acquiring an additional 143,142 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.